Environmental Persistence, Safety, and Sustainability Considerations of Nonionic Synthetic Stabilizers in Pharmaceutical Colloidal Drug Delivery Systems: A Review

Nonionic synthetic stabilizers are important excipients in colloidal drug delivery systems because they help preserve formulation integrity, enhance the solubilization of poorly water-soluble drugs, and improve product stability during storage. Common examples include polysorbates, poloxamers, polyethylene glycol (PEG)-based materials, polyvinyl alcohol, polyvinylpyrrolidone, and chemically modified cellulose materials. Despite their established pharmaceutical utility, increasing attention is directed toward the environmental consequences associated with their manufacture, application, degradation, transformation, and disposal. This review examines the environmental fate and sustainability implications of nonionic synthetic stabilizers used in colloidal drug delivery systems. Relevant peer-reviewed literature published between 1992 and 2026 was identified through searches of Scopus, PubMed, Web of Science, Science Direct, and Google Scholar. The review considers major stabilizer classes and stabilization mechanisms, sources and pathways of environmental entry, degradation processes, persistence, safety and ecotoxicological concerns, regulatory considerations, and emerging sustainable alternatives. Evidence indicates that pharmaceutical stabilizers may enter aquatic and terrestrial environments through manufacturing discharges, wastewater systems, pharmaceutical use, and inappropriate disposal. Their environmental behaviour varies according to chemical structure and physicochemical characteristics, and some substances or degradation products may exhibit persistence or potential ecological effects. Important gaps remain in long-term toxicological evidence, environmental surveillance, ecotoxicity assessment, and harmonization of regulatory approaches for pharmaceutical excipients. Emerging approaches involving biodegradable and renewable stabilizers, green chemistry, life-cycle assessment, and environmentally informed formulation design offer opportunities for reducing the ecological footprint of colloidal drug delivery systems. Future development should balance pharmaceutical functionality, patient safety, product quality, manufacturing feasibility, and environmental sustainability.

nonionic synthetic stabilizers, colloidal drug delivery, pharmaceutical excipients

1. Ajibola, A. S., Fawole, S. T., Ajibola, F. O., & Adewuyi, G. O. (2021). Diclofenac and ibuprofen determination in sewage sludge using a QuEChERS approach: Occurrence and ecological risk assessment in three Nigerian wastewater treatment plants. Bulletin of Environmental Contamination and Toxicology, 106(4), 690–699. [Google Scholar] [Crossref]

2. Alexandridis, P., & Hatton, T. A. (1995). Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: Thermodynamics, structure, dynamics, and modeling. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 96, 1–46. [Google Scholar] [Crossref]

3. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. Advanced Drug Delivery Reviews, 65, 36–48. [Google Scholar] [Crossref]

4. Anastas, P. T., & Warner, J. C. (1998). Green chemistry: Theory and practice. Oxford University Press. [Google Scholar] [Crossref]

5. Ansel, H. C., Allen, L. V., Jr., & Popovich, N. G. (2011). Ansel's pharmaceutical dosage forms and drug delivery systems (9th ed.). Lippincott Williams & Wilkins. [Google Scholar] [Crossref]

6. Anton, N., & Vandamme, T. F. (2011). Nano-emulsions and micro-emulsions: Clarifications of the critical differences. Pharmaceutical Research, 28, 978–985. [Google Scholar] [Crossref]

7. Aulton, M. E., & Taylor, K. M. G. (Eds.). (2017). Aulton's pharmaceutics: The design and manufacture of medicines (5th ed.). Elsevier. [Google Scholar] [Crossref]

8. Aus der Beek, T., Weber, F.-A., Bergmann, A., Hickmann, S., Ebert, I., Hein, A., & Küster, A. (2016). Pharmaceuticals in the environment—Global occurrences and perspectives. Environmental Toxicology and Chemistry, 35, 823–835. [Google Scholar] [Crossref]

9. Bading, M., Griffing, E., Olsson, O., Harris, J., Scher, J., Sakurai, A., Overcash, M., & Kümmerer, K. (2025). Assessments of life cycle and biodegradation properties uncovered distinct profiles of pharmaceutical excipients guiding selection for drug formulations. Green Chemistry, 27, 15568–15581. https://doi.org/10.1039/D5GC02518D. [Google Scholar] [Crossref]

10. Bading, M., Olsson, O., & Kümmerer, K. (2024). Assessing the aquatic biodegradation potential of polymeric excipients for pharmaceutical formulation. Chemosphere, 368, 143739. https://doi.org/10.1016/j.chemosphere.2024.143739. [Google Scholar] [Crossref]

11. Batrakova, E. V., & Kabanov, A. V. (2008). Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. Journal of Controlled Release, 130, 98–106. [Google Scholar] [Crossref]

12. Bhattacharjee, S. (2016). DLS and zeta potential—What they are and what they are not? Journal of Controlled Release, 235, 337–351. [Google Scholar] [Crossref]

13. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotechnology, 33, 941–951. [Google Scholar] [Crossref]

14. Bu, P., Narayanan, S., Dalrymple, D., Cheng, X., & Serajuddin, A. T. M. (2016). Cytotoxicity assessment of lipid-based self-emulsifying drug delivery system with Caco-2 cell model: Cremophor EL as the surfactant. European Journal of Pharmaceutical Sciences, 91, 162–171. [Google Scholar] [Crossref]

15. Campos, F. C., Victorino, V. J., Martins-Pinge, M. C., Cecchini, A. L., Panis, C., & Cecchini, R. (2014). Systemic toxicity induced by paclitaxel in vivo is associated with the solvent Cremophor EL through oxidative stress-driven mechanisms. Food and Chemical Toxicology, 68, 78–86. [Google Scholar] [Crossref]

16. Chiellini, E., Corti, A., D'Antone, S., & Solaro, R. (2003). Biodegradation of poly(vinyl alcohol) based materials. Progress in Polymer Science, 28, 963–1014. [Google Scholar] [Crossref]

17. Cortes, H., Hernandez-Parra, H., Bernal, S. A., Chavez, M. L., Del Prado-Audelo, I. H., Caballero-Floran, I. H., et al. (2021). Nonionic surfactants for stabilization of polymeric nanoparticles for biomedical uses. Materials, 14(12), 3197. [Google Scholar] [Crossref]

18. Danaei, M., Dehghankhold, M., Ataei, S., Hasanzadeh Davarani, F., Javanmard, R., Dokhani, A., Khorasani, S., & Mozafari, M. R. (2018). Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 10(2), 57. [Google Scholar] [Crossref]

19. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. Journal of Controlled Release, 161(2), 505–522. [Google Scholar] [Crossref]

20. Daughton, C. G., & Ternes, T. A. (1999). Pharmaceuticals and personal care products in the environment: Agents of subtle change? Environmental Health Perspectives, 107(Suppl. 6), 907–938. [Google Scholar] [Crossref]

21. Dumortier, G., Grossiord, J. L., Agnely, F., & Chaumeil, J. C. (2006). A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharmaceutical Research, 23, 2709–2728. [Google Scholar] [Crossref]

22. Fent, K., Weston, A. A., & Caminada, D. (2006). Ecotoxicology of human pharmaceuticals. Aquatic Toxicology, 76, 122–159. [Google Scholar] [Crossref]

23. George, A., Shah, P. A., & Shrivastav, P. S. (2019). Natural biodegradable polymers based nano-formulations for drug delivery: A review. International Journal of Pharmaceutics, 561, 244–264. [Google Scholar] [Crossref]

24. Grant, M. J., & Booth, A. (2009). A typology of reviews: An analysis of 14 review types and associated methodologies. Health Information & Libraries Journal, 26, 91–108. [Google Scholar] [Crossref]

25. Harris, J. M., & Chess, R. B. (2003). Effect of pegylation on pharmaceuticals. Nature Reviews Drug Discovery, 2, 214–221. [Google Scholar] [Crossref]

26. Heberer, T. (2002). Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: A review of recent research data. Toxicology Letters, 131, 5–17. [Google Scholar] [Crossref]

27. International Council for Harmonisation. (2009). ICH harmonised guideline Q8(R2): Pharmaceutical development. ICH. [Google Scholar] [Crossref]

28. International Organization for Standardization. (2006). ISO 14040:2006 environmental management—Life cycle assessment—Principles and framework. ISO. [Google Scholar] [Crossref]

29. Israelachvili, J. N. (2011). Intermolecular and surface forces (3rd ed.). Academic Press. [Google Scholar] [Crossref]

30. Jannin, V., Roddier, J. D., & Musakhanian, J. (2014). Polyglycerides and glycerides: Effects of manufacturing parameters on API stability, excipient functionality and processing. International Journal of Pharmaceutics, 466, 109–121. [Google Scholar] [Crossref]

31. Jiménez-González, C., Curzons, A. D., Constable, D. J. C., & Cunningham, V. L. (2004). Cradle-to-gate life cycle assessment of pharmaceutical compounds. The International Journal of Life Cycle Assessment, 9, 114–121. [Google Scholar] [Crossref]

32. Jiménez-González, C., Ponder, C. S., Broxterman, Q. B., & Manley, J. B. (2011). Using the right green yardstick: Why process mass intensity is used in the pharmaceutical industry to drive more sustainable processes. Organic Process Research & Development, 8, 513–516. [Google Scholar] [Crossref]

33. Julinová, M., Vaňharová, L., & Jurča, M. (2018). Water-soluble polymeric xenobiotics – Polyvinyl alcohol and polyvinylpyrrolidone – And potential solutions to environmental issues: A brief review. Journal of Environmental Management, 228, 213–222. https://doi.org/10.1016/j.jenvman.2018.09.010. [Google Scholar] [Crossref]

34. Kabanov, A. V., & Alakhov, V. Y. (2002). Pluronic block copolymers in drug delivery: From micellar nanocarriers to biological response modifiers. Critical Reviews in Therapeutic Drug Carrier Systems, 19, 1–72. [Google Scholar] [Crossref]

35. Kerwin, B. A. (2008). Polysorbates 20 and 80 used in the formulation of protein biotherapeutics: Structure and degradation pathways. Journal of Pharmaceutical Sciences, 97, 2924–2935. [Google Scholar] [Crossref]

36. Kishore, R. S. K., Kiese, S., Fischer, S., Pappenberger, A., Grauschopf, U., & Mahler, H.-C. (2011). The degradation of polysorbates 20 and 80 and its potential impact on the stability of biotherapeutics. Pharmaceutical Research, 28, 1194–1210. [Google Scholar] [Crossref]

37. Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010). Poly(ethylene glycol) in drug delivery: Pros and cons as well as potential alternatives. Angewandte Chemie International Edition, 49, 6288–6308. [Google Scholar] [Crossref]

38. Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014). PEG—A versatile conjugating ligand for drug delivery. Journal of Controlled Release, 192, 67–81. [Google Scholar] [Crossref]

39. Kümmerer, K. (2001). Drugs in the environment: Emission of drugs, diagnostic aids and disinfectants into wastewater by hospitals in relation to other sources—A review. Chemosphere, 45, 957–969. [Google Scholar] [Crossref]

40. Kümmerer, K. (2004). Pharmaceuticals in the environment: Sources, fate, effects and risks (2nd ed.). Springer. [Google Scholar] [Crossref]

41. Kümmerer, K. (2009). The presence of pharmaceuticals in the environment due to human use—Present knowledge and future challenges. Journal of Environmental Management, 90, 2354–2366. [Google Scholar] [Crossref]

42. Leal-Calderon, F., & Schmitt, V. (2008). Solid-stabilized emulsions. Current Opinion in Colloid & Interface Science, 13, 217–227. [Google Scholar] [Crossref]

43. Liu, Z., Jiao, Y., Wang, Y., Zhou, C., & Zhang, Z. (2008). Polysaccharides-based nano particles as drug delivery systems. Advanced Drug Delivery Reviews, 60(15), 1650–1662. [Google Scholar] [Crossref]

44. Luo, D., Wang, Y., Zhou, D., Wang, S., & Guo, M. (2026). Cellulose and its derivatives in drug delivery: Recent advances and applications. Pharmaceutics, 18, 594. [Google Scholar] [Crossref]

45. Maher, S., Geoghegan, C., & Brayden, D. J. (2023). Safety of surfactant excipients in oral drug formulation. Advanced Drug Delivery Reviews, 202, 115086. [Google Scholar] [Crossref]

46. Mahmoudi, M., & Serpooshan, V. (2012). Silver-coated engineered magnetic nanoparticles are promising for the successb in the fight against antibacterial resistance threat. ACS Nano, 6(3), 2656-2664. [Google Scholar] [Crossref]

47. Makadia, H. K., & Siegel, S. J. (2011). Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers, 3, 1377–1397. [Google Scholar] [Crossref]

48. Mason, T. G., Wilking, J. N., Meleson, K., Chang, C. B., & Graves, S. M. (2006). Nanoemulsions: Formation, structure, and physical properties. Journal of Physics: Condensed Matter, 18, R635–R666. [Google Scholar] [Crossref]

49. McClements, D. J. (2011). Edible nanoemulsions: Fabrication, properties, and functional performance. Soft Matter, 7, 2297–2316. [Google Scholar] [Crossref]

50. McClements, D. J. (2012). Nanoemulsions versus microemulsions: Terminology, differences, and similarities. Soft Matter, 8, 1719–1729. [Google Scholar] [Crossref]

51. McClements, D. J. (2015). Food emulsions: Principles, practices, and techniques (3rd ed.). CRC Press. [Google Scholar] [Crossref]

52. McDonough, K., Hall, M. J., Wilcox, A., Menzies, J., Brill, J., Morris, B., & Connors, K. (2024). Application of standardized methods to evaluate the environmental safety of polyvinyl alcohol disposed of down the drain. Integrated Environmental Assessment and Management, 20, 1693–1705. https://doi.org/10.1002/ieam.4929. [Google Scholar] [Crossref]

53. Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021). Engineering precision nanoparticles for drug delivery. Nature Reviews Drug Discovery, 20, 101–124. [Google Scholar] [Crossref]

54. Mura, S., & Couvreur, P. (2012). Nanotheranostics for personalized medicine. Advanced Drug Delivery Reviews, 64(13), 1394–1416. [Google Scholar] [Crossref]

55. Müller, R. H., Jacobs, C., & Kayser, O. (2001). Nanosuspensions as particulate drug formulations in therapy: Rationale for development and what we can expect for the future. Advanced Drug Delivery Reviews, 47(1), 3–19. [Google Scholar] [Crossref]

56. Ogunbanwo, O. M., Kay, P., Abagbor, R., et al. (2022). High concentration of pharmaceuticals in a Nigerian river catchment. Environmental Toxicology and Chemistry, 41(3), 551-558. [Google Scholar] [Crossref]

57. Olarinmoye, O., Bakare, A., Ugwumba, O and Hein, A. (2016). Quantification of pharmaceutical residues in wastewater impacted surface waters and sewage sludge from Lagos, Nigeria. Journal of Environmental Chemistry and Ecotoxicology, 8, 14–24. [Google Scholar] [Crossref]

58. Organisation for Economic Co-operation and Development. (1992). OECD guideline for testing of chemicals 301: Ready biodegradability. OECD Publishing. [Google Scholar] [Crossref]

59. Patra, J. K., Das, G., Fraceto, L. F., et al. (2018). Nano based drug delivery systems: Recent developments and future prospects. Journal of Nanobiotechnology, 16, 71. [Google Scholar] [Crossref]

60. Pifferi, G., & Restani, P. (2003). The safety of pharmaceutical excipients. Farmaco, 58, 541–550. [Google Scholar] [Crossref]

61. Pockle, R. D., Masareddy, R. S., Patil, A. S., & Patil, P. D. (2023). A comprehensive review on pharmaceutical excipients. Therapeutic Delivery, 14(7), 443–458. [Google Scholar] [Crossref]

62. Reker, D., Blum, S. M., Steiger, C., Anger, K. E., Sommer, J. M., Fanikos, J., & Traverso, G. (2019). “Inactive” ingredients in oral medications. Science Translational Medicine, 11(483), eaau6753. [Google Scholar] [Crossref]

63. Rolsky, C., Kelkar, V. P., & Halden, R. U. (2021). Degradation of polyvinyl alcohol in US wastewater treatment plants and subsequent nationwide emission estimate. International Journal of Environmental Research and Public Health, 18(11), 6027. [Google Scholar] [Crossref]

64. Rosen, M. J., & Kunjappu, J. T. (2012). Surfactants and interfacial phenomena (4th ed.). Wiley. [Google Scholar] [Crossref]

65. Rowe, R. C., Sheskey, P. J., & Quinn, M. E. (Eds.). (2009). Handbook of pharmaceutical excipients (6th ed.). Pharmaceutical Press. [Google Scholar] [Crossref]

66. Santos, L. H. M. L. M., Araújo, A. N., Fachini, A., Pena, A., Delerue-Matos, C., & Montenegro, M. C. B. S. M. (2010). Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment. Journal of Hazardous Materials, 175, 45–95. [Google Scholar] [Crossref]

67. Sarker, D. K. (2005). Engineering of nanoemulsions for drug delivery. Current Drug Delivery, 2(4), 297–310. [Google Scholar] [Crossref]

68. Schultz, M. M., Furlong, E. T., Kolpin, D. W., Werner, S. L., Schoenfuss, H. L., Barber, L. B., Blazer, V. S., Norris, D. O., & Vajda, A. M. (2010). Antidepressant pharmaceuticals in two U.S. streams: Occurrence and fate in water and sediment, and selective uptake in fish neural tissue. Environmental Science & Technology, 44(6), 1918–1925. [Google Scholar] [Crossref]

69. Scott, M. J., & Jones, M. N. (2000). The biodegradation of surfactants in the environment. Biochimica et Biophysica Acta, 1508, 235–251. [Google Scholar] [Crossref]

70. Serajuddin, A. T. M. (1999). Solid dispersion of poorly water-soluble drugs: Early promises, subsequent problems, and recent breakthroughs. Journal of Pharmaceutical Sciences, 88, 1058–1066. [Google Scholar] [Crossref]

71. Sheldon, R. A. (2007). The E factor: Fifteen years on. Green Chemistry, 9, 1273–1283. [Google Scholar] [Crossref]

72. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17, 20–37. [Google Scholar] [Crossref]

73. Solans, C., Izquierdo, P., Nolla, J., Azemar, N., & Garcia-Celma, M. J. (2005). Nano-emulsions. Current Opinion in Colloid & Interface Science, 10, 102–110. [Google Scholar] [Crossref]

74. Sun, B., Zhang, M., Shen, J., He, Z., Fatehi, P., & Ni, Y. (2019). Applications of cellulose-based materials in sustained drug delivery systems. Current Medicinal Chemistry, 26, 2485–2501. [Google Scholar] [Crossref]

75. Szebeni, J. (2005). Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity. Toxicology, 216, 106–121. [Google Scholar] [Crossref]

76. Tadros, T. F. (2013). Emulsion formation and stability. Wiley-VCH. [Google Scholar] [Crossref]

77. Tadros, T., Izquierdo, P., Esquena, J., & Solans, C. (2004). Formation and stability of nano-emulsions. Advances in Colloid and Interface Science, 108–109, 303–318. [Google Scholar] [Crossref]

78. Tarring, E. C., Robison-Smith, C., Ceballos-Ramirez, A. D., Durance, I., Harbottle, M. J., Cable, J., & Ward, B. D. (2025). Toxicity of the water-soluble polymer PVP is dependent on molecular weight and feed concentration for a freshwater model species. Science of the Total Environment, 983, 179686. https://doi.org/10.1016/j.scitotenv.2025.179686. [Google Scholar] [Crossref]

79. Torchilin, V. P. (2005). Recent advances with liposomes as pharmaceutical carriers. Nature Reviews Drug Discovery, 4, 145–160. [Google Scholar] [Crossref]

80. U.S. Food and Drug Administration. (2019). Using the inactive ingredient database: Guidance for industry. U.S. Department of Health and Human Services. [Google Scholar] [Crossref]

81. Uluseker, C., Lofts, S., & Harrison, S. (2025). Advances and challenges in modelling the environmental fate and exposure of pharmaceuticals: A comprehensive review. Environmental Science: Processes & Impacts, 27, 3700–3724. [Google Scholar] [Crossref]

82. Vasconcelos, T., Sarmento, B., & Costa, P. (2007). Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discovery Today, 12, 1068–1075. [Google Scholar] [Crossref]

83. Veronese, F. M., & Pasut, G. (2005). PEGylation, successful approach to drug delivery. Drug Discovery Today, 10, 1451–1458. [Google Scholar] [Crossref]

84. Virtanen, A. A., Lakio, S., Madi, A., & Sivén, M. (2026). Scoping review to identify data needs and environmental hotspots for future LCA studies: Insights into pharmaceutical excipients and processes. European Journal of Pharmaceutical Sciences, 107453. [Google Scholar] [Crossref]

85. Wang, H., Xi, H., Xu, L., Jin, M., Zhao, W., & Liu, H. (2021). Ecotoxicological effects, environmental fate and risks of pharmaceutical and personal care products in the water environment: A review. Science of the Total Environment, 788, 147819. [Google Scholar] [Crossref]

86. Wang, J., Li, X., Xu, J., et al. (2026). An overlooked environmental risk of a widely used non-ionic surfactant: Environmental toxicological effects of polysorbate 20 across life stages of the freshwater snail Biomphalaria glabrata. Ecotoxicology and Environmental Safety, 322, 120515. https://doi.org/10.1016/j.ecoenv.2026.120515. [Google Scholar] [Crossref]

87. Wang, Y., Zheng, Y., Zhang, L., Wang, Q., & Zhang, D. (2013). Stability of nanosuspensions in drug delivery. Journal of Controlled Release, 172(3), 1126–1141. [Google Scholar] [Crossref]

88. Weber, J., Buska, J., Mader, K., Garidel, P., & Diederich, T. (2023). Oxidation of polysorbates—An underestimated degradation pathway? International Journal of Pharmaceutica X, 6, 100020. [Google Scholar] [Crossref]

89. Ying, G.-G. (2006). Fate, behavior and effects of surfactants and their degradation products in the environment. Environment International, 32, 417–431. [Google Scholar] [Crossref]

90. Zakar-Jiya, A. Frazzoli, C. Obasi, CNA. Babatunde, BB. Patrick-Iwuanyawu, KC and Osakwe, OE. (2022). Pharmaceutical and personal care products as emerging environmental contaminants in Nigeria: A systematic review. Environmental Toxicology and Pharmacology, 93, 103876. [Google Scholar] [Crossref]

91. Zhang, Z., & Feng, S.-S. (2010). Nanoparticles of poly(lactide)-vitamin E TPGS copolymer for cancer chemotherapy. Biomaterials, 31, 8063–8070. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities